Skip to main content
. 2022 Feb 4;9:820151. doi: 10.3389/fmed.2022.820151

Figure 1.

Figure 1

Overview of sample origin. A total of 334 samples were tested. A commercial IgG ELISA (Euroimmun, Lübeck, Germany) was used for pre-screening. All but 30 samples were positive for SARS-CoV-2 IgG antibodies, of which 128 came from patients who had recently recovered from confirmed COVID-19 and 177 were from vaccinated individuals (collected at least three weeks after vaccination). In addition, 30 samples collected in mid to late 2018 served as negative control samples.